Comparative Pharmacology
Head-to-head clinical analysis: BREVIBLOC IN PLASTIC CONTAINER versus KERLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVIBLOC IN PLASTIC CONTAINER versus KERLONE.
BREVIBLOC IN PLASTIC CONTAINER vs KERLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Esmolol is a cardioselective beta-1 adrenergic receptor antagonist with minimal intrinsic sympathomimetic activity and membrane-stabilizing properties. At therapeutic doses, it blocks beta-1 receptors in the myocardium, decreasing heart rate, myocardial contractility, and AV conduction velocity, leading to reduced cardiac output and myocardial oxygen demand.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
Initial loading dose: 500 mcg/kg IV over 1 minute, followed by continuous IV infusion of 50 mcg/kg/min for 4 minutes; if inadequate response, repeat loading dose and increase infusion by 50 mcg/kg/min increments up to 200 mcg/kg/min. Maintenance: 25-200 mcg/kg/min continuous IV infusion.
10 mg orally once daily; may increase to 20 mg once daily if needed. Maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 9 minutes (range 4–15 minutes) for the parent drug, leading to rapid offset of effect. The half-life of the metabolite ASL-8123 is about 3.7 hours.
Terminal elimination half-life is 8-12 hours in healthy adults; may extend to 15-20 hours in renal impairment (CrCl <30 mL/min).
Elimination primarily via red blood cell esterases; renal excretion of unchanged drug is less than 1% of dose. Metabolite ASL-8123 is inactive and renally excreted.
Primarily renal excretion of unchanged drug and metabolites (70-80% unchanged; 20-30% as glucuronide or sulfate conjugates). Biliary/fecal excretion accounts for less than 5%.
Category C
Category C
Beta-Blocker
Beta-Blocker